On Tuesday, October 13, 2026, BioNTech announced that its experimental mRNA cancer immunotherapy BNT113 missed the first of two primary goals in the phase 2/3 AHEAD-MERIT trial for HPV16-positive head and neck cancer, sending its shares down about 6%. The setback is real — but the trial is not over: an independent monitoring committee recommended it continue toward its overall-survival readout, the second primary endpoint.
Illustration: Scientists developing an mRNA cancer vaccine in a biotechnology laboratory — a concept illustration, not a photograph of the trial.
What Happened
BioNTech, the German biotech company best known for its Pfizer-partnered Comirnaty COVID-19 vaccine, announced on Tuesday, October 13, 2026, that BNT113 — an mRNA immunotherapy also known as tenumomeran, or "tenu-ra" — failed to show a statistically significant improvement in progression-free survival (PFS) when added to Merck's Keytruda (pembrolizumab), compared with Keytruda alone, in the phase 2/3 AHEAD-MERIT trial (NCT04534205).
The trial enrolled about 285 patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma expressing PD-L1 (CPS ≥1), testing BNT113 plus Keytruda versus Keytruda alone as first-line treatment. Progression-free survival — how long patients live without their disease worsening — was the first of two co-primary endpoints. BioNTech did not disclose specific PFS hazard ratios, confidence intervals, or event counts, limiting independent assessment of how close the result came, according to Reuters.
Crucially, the study's independent data monitoring committee recommended the trial proceed as planned to evaluate the second co-primary endpoint: overall survival (OS). Under the pre-specified design, a statistically significant OS benefit would still establish a positive trial outcome despite the PFS miss.
Background
BNT113 works by encoding HPV16 E6 and E7 antigens — proteins made by the human papillomavirus — to induce an immune response against HPV16-positive tumor cells. Roughly one-third of head and neck cancers are HPV-positive, and there are currently no HPV-targeted treatments approved for head and neck cancer, which is why the field has watched this trial closely. BNT113 holds FDA fast-track designation, granted in January 2026.
Beating Keytruda in this setting has proven brutally hard: several earlier drug combinations have also failed to improve on pembrolizumab monotherapy in head and neck cancer. As Citi analyst Geoffrey Meacham noted, head and neck cancer "is heterogeneous and heavily immunosuppressed, making incremental efficacy over pembrolizumab challenging despite the HPV16 target," adding that prior cancer immunotherapies have won regulatory approvals after missing PFS but succeeding on overall survival.
For BioNTech, the result adds to a difficult oncology pivot: the company, which rose to fame on its COVID-19 vaccine, has been shifting toward cancer therapeutics and also reported a colorectal cancer study setback earlier in 2026, according to Reuters.
Illustration: A clinical trial infusion scene with immune cells attacking tumor cells — a concept illustration, not a photograph of the trial.
Why It Matters
The AHEAD-MERIT result is a bellwether for the entire mRNA cancer-vaccine field. BioNTech and Moderna are racing to prove that mRNA — the technology that transformed pandemic vaccination — can be turned into therapeutic cancer vaccines. A clear win in head and neck cancer would have been a landmark validation; the PFS miss means that validation remains out of reach for now.
But the story is not a verdict on mRNA cancer vaccines. BioNTech co-founder and chief medical officer Ozlem Tureci said the data "support continued evaluation" and show the drug is "engaging its intended therapeutic mechanism" — the therapy is doing what it was designed to do biologically, even if that has not yet translated into a measurable survival-before-progression advantage. And as the independent committee's decision shows, the trial's fate now rests on overall survival, historically the endpoint regulators care about most.
For patients, the unmet need is unchanged: HPV-driven head and neck cancers have no targeted treatment options, and standard immunotherapy alone remains the benchmark. The OS readout — timing not yet disclosed — will determine whether BNT113 becomes a new option or another combination that could not beat Keytruda.
What Happens Next
The AHEAD-MERIT trial continues with patients still being followed for overall survival, with BioNTech remaining blinded to the ongoing data, according to trial reporting. The OS analysis will be conducted per the pre-specified statistical plan; a significant OS benefit would salvage the trial.
Investors will also be watching BioNTech's broader oncology pipeline for readouts that could rebuild confidence after the ~6% share drop. Beyond this trial, the mRNA cancer-vaccine field faces a credibility test: Moderna's personalized vaccine in melanoma and BioNTech's programs in other cancers will be read through the lens of the BNT113 outcome.
An editorial caution: this is an interim, investigational result. It neither proves nor disproves mRNA cancer vaccines as a class, and patients should not interpret the trial's continuation as a sign of hidden good news — or the PFS miss as proof the approach has failed.
Illustration: HPV virus particles under attack by immune cells — a concept illustration, not a photograph.
Sponsored: explore today's featured sponsored offers
FAQ
What is BNT113?
BNT113 is BioNTech's experimental mRNA cancer immunotherapy, which encodes HPV16 E6 and E7 antigens to trigger an immune response against HPV16-positive tumor cells. It is investigational and not approved by any regulator.
What did the trial actually find?
In the phase 2/3 AHEAD-MERIT trial, BNT113 plus Keytruda did not significantly improve progression-free survival versus Keytruda alone in HPV16-positive head and neck cancer. The trial continues toward its second primary endpoint, overall survival.
Does the PFS miss mean the trial failed?
Not necessarily. Under the trial's pre-specified design, a statistically significant overall-survival benefit would still make it a positive trial, and the independent monitoring committee recommended it continue to that readout.
What is HPV16-positive head and neck cancer?
It is a type of head and neck squamous cell carcinoma driven by infection with human papillomavirus type 16. Roughly one-third of head and neck cancers are HPV-positive, and there are no approved HPV-targeted treatments for them.
Should patients change their treatment based on this news?
No. This is an investigational-trial result, and treatment decisions should always be made with an oncologist. The trial result does not change the approved standard of care for head and neck cancer.
Sources
- Reuters — "BioNTech's mRNA cancer therapy misses first goal in head-neck trial" — published October 13, 2026
- BioPharma Dive — "BioNTech mRNA immunotherapy HPV16 head-neck cancer" (Delilah Alvarado) — published October 13, 2026
- BioPharm International — "BioNTech BNT113 PFS miss head-neck cancer" — October 2026, citing BioNTech's October 13, 2026 press release
Comments
Post a Comment